| Insider · 15 positions | Net Shares per Quarter (+ Bought / − Sold) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Name | Role | Shares Held ↓ | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
| Alexis Borisy | — | 2.3M | — | +4K | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Stephen Michael Kelsey | President, Research and Development | 292K | — | -4K | +64K | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Mark A Goldsmith | President and Chief Executive Officer | 267K | — | -130K | +137K | -15K | — | — | — | — | — | — | — | — | — | — | — | — |
| Margaret A Horn | Chief Operating Officer | 184K | — | -100K | -11K | — | — | -4K | — | — | — | — | — | — | — | — | — | — |
| Jack Anders | Chief Financial Officer | 143K | — | +17K | +53K | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Xiaolin Wang | EVP, Clinical Development | 116K | — | — | +47K | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Lin Wei | Chief Medical Officer | 101K | — | — | +47K | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Sandra Horning | — | 98K | — | +4K | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Lorence H. Kim | — | 74K | — | +4K | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Jeff Cislini | General Counsel | 57K | — | -2K | +43K | -3K | — | — | — | — | — | — | — | — | — | — | — | — |
| Anthony Mancini | Chief Global Commercialization Officer | 50K | — | -11K | -37K | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Sushil Patel | — | 27K | — | -1K | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Flavia Borellini | — | 26K | — | +4K | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Frank Clyburn | — | 11K | — | +4K | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Elizabeth M Anderson | — | 9K | — | +4K | — | — | — | — | — | — | — | — | — | — | — | — | — | — |